

Supplemental Table 1. (Fasting visits only)

Conventional lipid profiles

Lipids	Visit	DM PE+	^a p	DM PE-	^b p	DM-
N*		22		62		18
Total cholesterol (mg/dL)	1	183 ± 29	0.49	177 ± 30	0.17	188 ± 26
	2	241 ± 47	0.07	221 ± 35	0.16	236 ± 41
	3	267 ± 45	0.77	264 ± 51	0.79	267 ± 48
	Term	-	-	268 ± 74	0.49	289 ± 63
LDL-cholesterol (mg/dL)	1	88 ± 13	0.05	75 ± 14	0.40	82 ± 16
	2	120 ± 18	0.06	103 ± 16	0.28	114 ± 21
	3	151 ± 24	0.32	139 ± 27	0.67	134 ± 17
	Term	-	-	127 ± 37	0.40	154 ± 34
Triglycerides (mg/dL)	1	76 ± 9	0.35	71 ± 13	0.11	79 ± 8
	2	135 ± 20	0.07	118 ± 17	0.30	129 ± 23
	3	180 ± 33	0.82	177 ± 37	0.36	161 ± 31
	Term	-	-	218 ± 34	0.38	247 ± 38
VLDL-cholesterol (mg/dL)	1	15 ± 2	0.35	14 ± 3	0.11	16 ± 2
	2	27 ± 4	0.07	24 ± 3	0.69	23 ± 6
	3	38 ± 5	0.39	36 ± 7	0.31	32 ± 6
	Term	-	-	44 ± 7	0.68	46 ± 6
HDL-cholesterol (mg/dL)	1	75 ± 16	0.08	82 ± 18	0.93	83 ± 24
	2	89 ± 20	0.97	89 ± 20	0.54	86 ± 23
	3	72 ± 11	0.12	77 ± 17	0.41	81 ± 19
	Term	-	-	78 ± 18	0.72	75 ± 24

*Mean N confirmed fasting in each group. Values are shown as mean ± SD. For conversion to SI unit (mmol/L), multiply by 0.02586 (cholesterol) and 0.01129 (triglycerides).

^ap: DM PE+ versus DM PE-, ^bp: DM PE- versus DM-.

DM, Diabetes Mellitus, DM-, non-diabetic controls, PE+, Pre-eclampsia, PE-, no Pre-eclampsia.

⌋ Significant increase (time trend analyses, visits 1-3; p<0.01)

Supplemental Table 2. (Fasting visits only)

NMR-derived lipid profiles

Lipids N*	Visit	DM PE+ 22	^a p	DM PE- 62	^b p	DM- 18
Total LDL particles (nmol/L)	1	937 ± 135	0.01	759 ± 151	0.33	847 ± 181
	2	1193 ± 170	0.02	1000 ± 157	0.24	1133 ± 244
	3	1488 ± 233	0.11	1311 ± 210	0.24	1486 ± 327
	Term	-	-	1282 ± 236	0.31	1575 ± 424
IDL particles (nmol/L)	1	39 ± 56	0.15	20 ± 36	0.56	30 ± 63
	2	63 ± 68	0.37	48 ± 69	0.10	83 ± 79
	3	163 ± 101	0.56	147 ± 118	0.59	130 ± 124
	Term	-	-	208 ± 143	0.80	194 ± 106
Large LDL particles (nmol/L)	1	545 ± 171	0.14	481 ± 176	0.18	536 ± 139
	2	919 ± 255	0.05	794 ± 237	0.97	796 ± 260
	3	1004 ± 279	0.61	966 ± 341	0.99	965 ± 298
	Term	-	-	951 ± 377	0.67	898 ± 226
Small LDL particles (nmol/L)	1	390 ± 235	0.24	314 ± 314	0.71	352 ± 382
	2	259 ± 402	0.57	206 ± 290	0.22	356 ± 498
	3	392 ± 445	0.24	262 ± 388	0.15	534 ± 783
	Term	-	-	198 ± 340	0.15	689 ± 904
Medium small LDL particles (nmol/L)	1	77 ± 44	0.49	68 ± 66	0.83	72 ± 76
	2	46 ± 72	0.89	43 ± 59	0.27	69 ± 95
	3	66 ± 77	0.43	51 ± 73	0.17	99 ± 147
	Term	-	-	43 ± 64	0.19	121 ± 159
Very small LDL particles (nmol/L)	1	313 ± 195	0.20	246 ± 254	0.68	280 ± 308
	2	214 ± 330	0.51	163 ± 236	0.22	287 ± 405
	3	325 ± 369	0.21	211 ± 317	0.14	435 ± 636
	Term	-	-	155 ± 277	0.14	568 ± 745
Total VLDL + Chylomicron particles (nmol/L)	1	25 ± 19	0.67	27 ± 22	0.56	29 ± 12
	2	46 ± 33	0.57	41 ± 26	0.27	48 ± 24
	3	90 ± 58	0.64	83 ± 54	0.65	77 ± 44
	Term	-	-	97 ± 43	0.17	130 ± 60

Large VLDL + Chylomicron particles (nmol/L)	1	●	0.7 ± 0.8	0.91	●	0.6 ± 1.1	0.50	●	1.1 ± 2.6
	2	┆	0.8 ± 0.8	0.07	┆	1.4 ± 2.3	0.48	┆	1.9 ± 2.2
	3	●	3.1 ± 2.4	0.65	●	3.4 ± 4.1	0.86	●	3.3 ± 3.5
	Term		-	-		4.3 ± 4.4	0.89		4.5 ± 3.1
Medium VLDL particles (nmol/L)	1	●	8 ± 5	0.07	●	12 ± 9	0.48	●	13 ± 10
	2	┆	21 ± 14	0.62	┆	19 ± 12	0.60	┆	22 ± 15
	3	●	40 ± 29	0.87	●	33 ± 22	0.87	●	34 ± 19
	Term		-	-		38 ± 20	0.06		63 ± 32
Small VLDL particles (nmol/L)	1	●	16 ± 15	0.79	●	15 ± 16	0.62	●	13 ± 9
	2	┆	21 ± 18	0.81	┆	20 ± 16	0.28	┆	25 ± 16
	3	●	47 ± 36	0.48	●	41 ± 27	0.45	●	40 ± 29
	Term		-	-		55 ± 32	0.56		63 ± 33
<hr/>									
Total HDL particles (μmol/L)	1		32 ± 5	0.18		30 ± 6	0.40		31 ± 4
	2		35 ± 6	0.26		34 ± 6	0.82		34 ± 5
	3		34 ± 5	0.77		33 ± 5	0.61		32 ± 5
	Term		-	-		35 ± 8	0.45		33 ± 5
Large HDL particles (μmol/L)	1		11 ± 2	0.22		12 ± 3	0.90		12 ± 3
	2		14 ± 3	0.73		14 ± 3	0.21		13 ± 3
	3		13 ± 3	0.99		13 ± 3	0.30		12 ± 3
	Term		-	-		13 ± 3	0.17		11 ± 3
Medium HDL particles (μmol/L)	1	●	2.9 ± 3.2	0.34	●	2.1 ± 3.0	0.57	●	1.7 ± 2.8
	2	┆	1.2 ± 2.6	0.64	┆	0.9 ± 1.9	0.55	┆	1.5 ± 3.8
	3	●	0.4 ± 0.8	0.33	●	0.7 ± 1.9	0.64	●	0.5 ± 1.5
	Term		-	-		1.0 ± 2.0	0.08		0.03 ± 0.1
Small HDL particles (μmol/L)	1	●	17 ± 5	0.33	●	15 ± 5	0.28	●	17 ± 5
	2	┆	20 ± 5	0.23	┆	19 ± 5	0.62	┆	19 ± 6
	3	●	20 ± 5	0.67	●	20 ± 5	0.98	●	20 ± 6
	Term		-	-		21 ± 6	0.70		21 ± 5

* Mean N confirmed fasting in each group. Values are shown as mean ± SD.

^ap: DM PE+ versus DM PE-, ^bp: DM PE- versus DM-, p values <0.05 are shown in boldface.

DM, Diabetes Mellitus, DM-, non-diabetic controls, PE+, Pre-eclampsia, PE-, no Pre-eclampsia.

● Significant increase (except decrease in medium HDL) (time trend analyses, visits 1-3; p<0.01)

Supplemental Table 3. (Fasting visits only)

ADLS -based lipid profiles

Lipids	Visit	DM PE+	^a p	DM PE-	^b p	DM-
N*		22		62		18
Lp-B (mg/dL)	1	53 ± 6	0.17	51 ± 4	0.07	54 ± 5
	2	62 ± 8	0.57	61 ± 5	0.21	62 ± 5
	3	68 ± 7	0.47	67 ± 6	0.84	68 ± 8
	Term	-	-	65 ± 7	0.20	70 ± 10
Lp-B:C (mg/dL)	1	10 ± 3	0.88	10 ± 4	0.32	11 ± 4
	2	13 ± 4	0.10	11 ± 4	0.16	12 ± 4
	3	11 ± 5	0.98	11 ± 4	0.77	11 ± 4
	Term	-	-	12 ± 6	0.55	10 ± 4
Lp-B:E + Lp-B:C:E (mg/dL)	1	12 ± 3	0.68	11 ± 4	0.95	11 ± 4
	2	12 ± 5	0.75	11 ± 5	0.93	11 ± 4
	3	15 ± 6	0.63	14 ± 5	0.40	16 ± 6
	Term	-	-	17 ± 6	0.89	17 ± 5
Lp-All:B:C:D:E (mg/dL)	1	11 ± 5	0.67	10 ± 4	0.09	13 ± 5
	2	12 ± 4	0.31	11 ± 5	0.37	12 ± 5
	3	16 ± 8	0.68	15 ± 7	0.63	15 ± 7
	Term	-	-	17 ± 7	0.13	22 ± 7
Lp-AI (mg/dL)	1	39 ± 3	0.83	39 ± 3	0.76	39 ± 4
	2	41 ± 3	0.76	40 ± 3	0.11	39 ± 3
	3	39 ± 3	0.51	39 ± 4	0.63	40 ± 3
	Term	-	-	39 ± 4	0.55	39 ± 4
Lp-AI:All (mg/dL)	1	110 ± 8	0.49	112 ± 11	0.99	112 ± 11
	2	124 ± 12	0.36	122 ± 11	0.10	126 ± 9
	3	113 ± 11	0.16	118 ± 13	0.38	115 ± 10
	Term	-	-	114 ± 14	0.90	114 ± 12

*Mean N confirmed fasting in each group. Values are shown as mean ± SD.

^ap: DM PE+ versus DM PE-, ^bp: DM PE- versus DM-.

DM, Diabetes Mellitus, DM-, non-diabetic controls, PE+, Pre-eclampsia, PE-, no Pre-eclampsia, ADLS, apolipoprotein-defined lipoprotein subclass

⌋ Significant increase (time trend analyses, visits 1-3; $p < 0.01$)

Supplemental Table 4. (Fasting visits only)

Apo CIII- sub fractions

Lipids N*	Visit	DM PE+ 22	^a p	DM PE- 62	^b p	DM- 18
Apo CIII (mg/dL)	1	10 ± 3	0.10	11 ± 3	0.93	11 ± 3
	2	15 ± 5	0.78	14 ± 3	0.27	15 ± 3
	3	18 ± 5	0.55	19 ± 5	0.07	17 ± 3
	Term	-	-	21 ± 5	0.49	23 ± 3
Apo CIII-HS (mg/dL)	1	7 ± 2	0.12	8 ± 2	0.79	8 ± 2
	2	10 ± 3	0.90	10 ± 2	0.88	10 ± 2
	3	10 ± 3	0.27	11 ± 3	0.09	10 ± 2
	Term	-	-	12 ± 3	0.69	12 ± 3
Apo CIII-HP (mg/dL)	1	3 ± 1	0.60	3 ± 1	0.51	3 ± 1
	2	5 ± 2	0.39	4 ± 1	0.27	5 ± 1
	3	8 ± 3	0.51	7 ± 2	0.25	7 ± 2
	Term	-	-	9 ± 3	0.40	10 ± 4
Apo CIII-HS/HP (mg/dL)	1	2.4 ± 0.5	0.01	2.8 ± 0.7	0.50	2.7 ± 0.8
	2	2.3 ± 0.8	0.42	2.5 ± 0.8	0.49	2.3 ± 0.9
	3	1.4 ± 0.6	0.20	1.6 ± 0.6	0.60	1.7 ± 0.8
	Term	-	-	1.5 ± 0.5	0.60	1.4 ± 0.7

*Mean N confirmed fasting in each group. Values are shown as mean ± SD.

^ap: DM PE+ versus DM PE-, ^bp: DM PE- versus DM-, p values <0.05 are shown in boldface.

DM, Diabetes Mellitus, DM-, non-diabetic controls, PE+, Pre-eclampsia, PE-, no Pre-eclampsia

⌋ Significant increase (except decrease in Apo CIII-HS/HP) (time trend analyses, visits 1-3; p<0.01)

Supplemental Table 5. (Fasting visits only)

Serum apolipoproteins

Apolipoproteins	Visit	DM PE+	^ap	DM PE-	^bp	DM-
N*		22		62		18
Apo AI (mg/dL)	1	174 ± 29	0.20	184 ± 32	0.80	186 ± 39
	2	215 ± 42	0.86	217 ± 36	0.56	212 ± 32
	3	205 ± 28	0.31	213 ± 40	0.09	197 ± 34
	Term	-	-	212 ± 43	0.41	199 ± 34
Apo B (mg/dL)	1	83 ± 19	0.23	77 ± 19	0.16	84 ± 16
	2	117 ± 28	0.07	105 ± 24	0.24	114 ± 30
	3	146 ± 35	0.26	136 ± 31	0.39	144 ± 35
	Term	-	-	151 ± 50	0.50	165 ± 51
Apo B/ Apo AI	1	0.5 ± 0.1	0.05	0.4 ± 0.1	0.32	0.5 ± 0.1
	2	0.5 ± 0.1	0.08	0.5 ± 0.1	0.31	0.5 ± 0.1
	3	0.7 ± 0.1	0.32	0.7 ± 0.1	0.25	0.7 ± 0.1
	Term	-	-	0.7 ± 0.1	0.36	0.8 ± 0.2
Lp (a) (mg/dL)	1	13 ± 11	0.84	14 ± 8	0.83	15 ± 12
	2	16 ± 16	0.64	14 ± 8	0.77	12 ± 9
	3	15 ± 13	0.64	13 ± 9	0.91	14 ± 10
	Term	-	-	15 ± 9	0.71	12 ± 12

*Mean N confirmed fasting in each group. Values are shown as mean ± SD.

^ap: DM PE+ versus DM PE-, ^bp: DM PE- versus DM-.

DM, Diabetes Mellitus, DM-, non-diabetic controls, PE+, Pre-eclampsia, PE-, no Pre-eclampsia.

● Significant increase (time trend analyses, visits 1-3; p<0.01)